ANAPTYSBIO, INC
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
ANAB$46.45+1.9%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets as of September, 2025 and December 31, 2024
Consolidated Balance Sheets
(in thousands, except par value data)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $109,833 | $123,080 |
| Receivables from collaborative partners | 75,685 | 40,765 |
| Short-term investments | 139,123 | 262,293 |
| Prepaid expenses and other current assets | 6,009 | 5,738 |
| Total current assets | 330,650 | 431,876 |
| Property and equipment, net | 1,500 | 1,849 |
| Operating lease right-of-use assets | 12,994 | 14,383 |
| Long-term investments | 7,698 | 35,470 |
| Other long-term assets | 256 | 256 |
| Total assets | $353,098 | $483,834 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $2,893 | $4,002 |
| Accrued expenses | 33,171 | 39,501 |
| Current portion of operating lease liability | 2,040 | 1,925 |
| Total current liabilities | 38,104 | 45,428 |
| Liability related to sale of future royalties | 331,844 | 353,426 |
| Operating lease liability, net of current portion | 12,566 | 14,112 |
| Stockholders’ (deficit) equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at September 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.001 par value, 500,000 shares authorized, 27,575 shares and 30,473 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 28 | 30 |
| Additional paid in capital | 792,682 | 829,860 |
| Accumulated other comprehensive gain | 47 | 305 |
| Accumulated deficit | (822,173) | (759,327) |
| Total stockholders’ (deficit) equity | (29,416) | 70,868 |
| Total liabilities and stockholders’ (deficit) equity | $353,098 | $483,834 |
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Collaboration revenue | $76,320 | $30,017 | $126,354 | $48,167 |
| Operating expenses: | ||||
| Research and development | 31,407 | 42,212 | 110,411 | 121,251 |
| General and administrative | 10,209 | 10,562 | 34,948 | 32,195 |
| Total operating expenses | 41,616 | 52,774 | 145,359 | 153,446 |
| Income (loss) from operations | 34,704 | (22,757) | (19,005) | (105,279) |
| Other income (expense), net: | ||||
| Interest income | 2,924 | 5,324 | 10,991 | 14,531 |
| Non-cash interest expense for the sale of future royalties | (22,515) | (15,413) | (60,182) | (32,683) |
| Other (expense) income, net | — | (5) | 5,433 | (7) |
| Total other expense, net | (19,591) | (10,094) | (43,758) | (18,159) |
| Income (loss) before income taxes | 15,113 | (32,851) | (62,763) | (123,438) |
| Provision for income taxes | — | — | (83) | (9) |
| Net income (loss) | 15,113 | (32,851) | (62,846) | (123,447) |
| Unrealized gain (loss) on available for sale securities | 53 | 1,174 | (258) | 1,556 |
| Comprehensive income (loss) | $15,166 | $(31,677) | $(63,104) | $(121,891) |
| Net income (loss) per common share: | ||||
| Basic | $0.54 | $(1.14) | $(2.16) | $(4.46) |
| Diluted | $0.52 | $(1.14) | $(2.16) | $(4.46) |
| Weighted-average number of shares outstanding: | ||||
| Basic | 27,833 | 28,893 | 29,085 | 27,688 |
| Diluted | 29,018 | 28,893 | 29,085 | 27,688 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.